Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Attix Pharmaceuticals Inc
WARNING LETTER
•Attix Pharmaceuticals Inc•November 14, 2014

Attix Pharmaceuticals Inc – FDA Warning Letter, Nov 14, 2014

Record Details

This FDA Warning Letter, dated June 22, 2015, was issued to Attix Pharmaceuticals following an inspection from November 10-14, 2014, at their Toronto, Canada facility. The inspection identified significant deviations from current Good Manufacturing Practice (CGMP) for Active Pharmaceutical Ingredients (APIs), rendering their APIs adulterated under Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act.

Key violations include: 1. **Failure to prevent cross-contamination of beta-lactam drug products:** Attix Pharmaceuticals failed to use separate facilities, dedicated equipment (e.g., hoods), or air handling systems for manufacturing penicillins, non-penicillin beta-lactams, and non-beta-lactam APIs. Personnel and materials moved freely between areas, increasing cross-contamination risk. The firm's response, detailing HEPA-filtered hoods and cleaning with (b)(4), was deemed insufficient as cleaning cannot substitute for proper segregation, and no scientific justification for using (b)(4) to inactivate beta-lactam rings was provided. The FDA emphasized that no safe level of penicillin contamination exists due to severe allergenic reactions. 2. **Failure to accurately transfer expiry dates:** An internal audit revealed 186 instances where the firm inaccurately transferred manufacturer-assigned expiry/retest dates to customers, extending them by up to (b)(

Company
Attix Pharmaceuticals Inc
Inspection date
November 14, 2014
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Thomas J. Cosgrove
View Company Profile

ID · 3cbfdd76-8df0-420e-bbc9-0995888891de

Violation Codes4
21 U.S.C. 381(a)(3)FD&C Act 501(a)(2)(B)FD&C Act 801(a)(3)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Attix Pharmaceuticals Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.